COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Cambridge Finance Workshop Series > Monitoring Secretive Startups
Monitoring Secretive StartupsAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Cerf Admin. This article examines the mechanisms used by venture capitalists (VCs) to monitor their investments in startups that use trade secrets to protect their intellectual property (IP). First, we confirm that, after startups are afforded stronger trade secrets protection by the adoption of the Uniform Trade Secrets Act (UTSA), they reduce their reliance on patents. Next, we investigate how VCs respond, finding that they decrease both the duration of financing rounds and the overall amount invested per round, especially for startups located the furthest distance away. Finally, we consider how these collective changes affect the exiting process, finding that the likelihood of a successful exit through either an initial public offering (IPO) or merger or acquisition (M&A) is unchanged, but that, within successful M&A exits, the likelihood that the acquirer is private increases. Overall, our findings suggest that VCs work harder to monitor startups that use trade secrets and that this increased effort is necessary to maintain similar likelihoods of successful exiting. This talk is part of the Cambridge Finance Workshop Series series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsSIAM-IMA Cambridge Student Chapter Computer Laboratory NetOS Group Talklets Birkbeck LecturesOther talksPredicting Nonlinear Vibration Response Under Combined Harmonic and Random Excitation TNG Technology Consulting: Where Am I and What's That? - SLAM The Fundamental Plane: between galaxy evolution and cosmology BSU Virtual Seminar: “Estimating treatment effects from adaptive clinical trials” Enhancing Reduced-order Models Using Insights from Nonlinear Modal Interactions Computational Oncology at AstraZeneca |